Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

@article{Khoury2021NeutralizingAL,
  title={Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.},
  author={David S. Khoury and Deborah Cromer and Arnold Reynaldi and Timothy E. Schlub and Adam K. Wheatley and Jennifer A. Juno and Kanta Subbarao and Stephen J. Kent and James A. Triccas and Miles P. Davenport},
  journal={Nature medicine},
  year={2021}
}
Predictive models of immune protection from COVID-19 are urgently needed to identify correlates of protection to assist in the future deployment of vaccines. To address this, we analyzed the relationship between in vitro neutralization levels and the observed protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection using data from seven current vaccines and from convalescent cohorts. We estimated the neutralization level for 50% protection against detectable SARS… Expand
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
TLDR
Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS- CoV-2 and can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines. Expand
Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody Levels
TLDR
This work demonstrates that appropriately calibrated neutralizing antibody measurements determined by a high throughput surrogate viral neutralization test can be used to provide a semi-quantitative estimate of protection against infection. Expand
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
TLDR
It is shown that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against SARS-CoV-2 and the Alpha and Beta variants, which suggests that continued antibody maturation improves tolerance to spike mutations. Expand
An immune correlate of SARS-CoV-2 infection and severity of reinfections
TLDR
Prior infection-induced immunity is protective against infection when predominantly gamma and delta SARS-CoV-2 circulated, and the protective antibody titers presented may be useful for vaccine policy and control measures. Expand
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic Infection
TLDR
Quantitative neutralizing and binding antibody concentrations were strongly positively correlated and were noted to be several fold lower in the unvaccinated study population as compared to published data on concentrations noted 28 days post-vaccination, which support observations of infection-induced immunity and current recommendations for vaccination post infection. Expand
Correlates of Protection against symptomatic and asymptomatic SARS-CoV-2 infection
TLDR
Correlates of protection can be used to bridge to new populations using validated assays and extrapolate efficacy estimates for new vaccines where large efficacy trials cannot be conducted. Expand
Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection
TLDR
The data suggest that symptomatic COVID-19 disease is followed by relatively long-lived protection from re-infection by antigenically similar viruses. Expand
Immunity to SARS-CoV-2 up to 15 months after infection
TLDR
The data suggest that antiviral specific immunity especially memory B cells in COVID-19 convalescent patients is long-lasting, but some variants of concern, including the fast-spreading Delta variant, may at least partially escape the neutralizing activity of plasma antibodies. Expand
SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection
  • Yan Zhan, Yufang Zhu, +22 authors Peng Hong
  • Medicine
  • Signal Transduction and Targeted Therapy
  • 2021
TLDR
The findings suggest long-lasting immune protection after SARS-CoV-2 infection, while also highlighting the risk of immune evasive variants and long-term consequences for COVID-19 survivors. Expand
Defective neutralizing antibody response to SARS-CoV-2 in vaccinated dialysis patients
TLDR
Cutting neutralizing activity correlated with low antibody avidity, consistent with a delayed affinity maturation of SARS-CoV-2 S-specific B cells, indicates that dialysis patients should be considered for an additional boost and other therapeutic strategies, including early immunotherapy with monoclonal antibodies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
TLDR
A role for potent neutralizing antibodies (nAbs) in prophylaxis, and potentially therapy, of COVID-19 is suggested, as indicated by maintained weight and low lung viral titers in treated animals, and the passive transfer of a nAb provides protection against disease in high-dose SARS-CoV-2 challenge in Syrian hamsters. Expand
Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
TLDR
It is demonstrated that relatively low antibody titers are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may also contribute to protection if antibody responses are suboptimal. Expand
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
TLDR
The dynamics of memory responses to SARS-CoV-2 and the mechanisms of immune control are crucial for the rational design and deployment of vaccines and for understanding the possible future trajectories of the pandemic. Expand
Evolution of antibody immunity to SARS-CoV-2.
TLDR
The humoral memory response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence, and the antibodies expressed have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral response. Expand
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
TLDR
It is indicated that SARS-CoV-2 immunity after infection might be transiently protective at a population level and might require greater immunogenicity and durability than natural infection to drive long-term protection. Expand
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
TLDR
Results show that durable immunity against secondary COVID-19 disease is a possibility for most individuals, and assessing virus-specific immune memory over at least a 6-month period is likely necessary to ascertain the durability of immune memory to SARS-CoV-2. Expand
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
TLDR
The hypothesis that the quality of the neutralizing immune response against SARS-CoV-2 evolves over the post-convalescent stage is reinforced, as individuals with mild or asymptomatic infection experienced an insignificant decay in neutralizing activity, which persisted six months after symptom onset or diagnosis. Expand
Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models
TLDR
A selection of existing assays for measuring antibody-mediated virus neutralization and animal models of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are analyzed and a framework for comparing results between studies and reconciling observed differences in the effects of interventions is provided. Expand
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
TLDR
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified. Expand
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
TLDR
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine. Expand
...
1
2
3
4
5
...